Development of thalidomide and its IMiD derivatives

Cindy H. Chau, William Dahut, William D. Figg*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Despite its controversial past, the establishment of thalidomide as an anti-inflammatory, immunomodulatory, and antiangiogenic agent bolstered intense research into its mechanism of action and therapeutic range. The precise pharmacologic mechanism through which thalidomide exerts its activity is complex and not fully understood. The enhancement of thalidomide's immunomodulatory effects while minimizing the adverse reactions brought about a class of novel analogues termed the Immunomodulatory drugs (IMiDs). This chapter reviews and highlights some of the clinical activities and development of thalidomide and its IMiDs derivatives in the treatment of hematological cancers and various solid tumors.

Original languageEnglish
Title of host publicationAngiogenesis
Subtitle of host publicationAn Integrative Approach From Science to Medicine
PublisherSpringer US
Number of pages8
ISBN (Print)9780387715179
StatePublished - 2008
Externally publishedYes


  • immunomodulatory drugs
  • lenalidomide
  • multiple myeloma
  • thalidomide


Dive into the research topics of 'Development of thalidomide and its IMiD derivatives'. Together they form a unique fingerprint.

Cite this